Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 4 2Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 130Thoracic 44Head & Neck 27Breast 23Sarcoma 22Gynecologic 21CNS 6Dermatologic 5Endocrine 4Other solid neoplasm 3Tumor-Agnostic 2Genitourinary 2Other neoplasm 1NET 1Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1

Interventions

Rituximab 689Cyclophosphamide 614Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 228Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 175Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106Tacrolimus 105obinutuzumab 104Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × apatinib × Lymphoid × Clear all
NCT03701022 2018-10-09

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Peking University

Phase 2 Unknown
61 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡